Clario Holdings, Inc

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°CNet-Zero: Targets set

SBTI ID

40004913

Informations générales

Localisation

United States of America

Northern America

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

29/08/2024

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon 2030

Statut

Targets set

Classification

1.5°C

Année cible

2030

Progression vers l'objectif73%
2015 (année de référence)2030
Objectifs à long terme (Long-Term)
Engagement de réduction des émissions à horizon 2045

Statut

Targets set

Classification

1.5°C

Année cible

2045

Progression vers l'objectif37%
2015 (année de référence)2045
Description complète des objectifs

Overall Net-Zero Target: Clario Holdings, Inc. commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: Clario Holdings, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 63.6% by 2030 from a 2021 base year. Clario Holdings, Inc. also commits to reduce absolute scope 3 GHG emissions 25% within the same timeframe. Long-Term Targets: Clario Holdings, Inc. commits to reduce absolute scope 1, 2 and 3 GHG emissions 90% by 2045 from a 2021 base year.

Net-Zero

Statut

Targets set

Année cible

2045

Progression37%
Business Ambition 1.5°C

Statut

BA1.5 member

Date d'engagement

14/07/2022

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

LEI

2549003SUFVGC903CK03

Source : Science Based Targets initiative | Données publiques